Strongyloidiasis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
m (Changes made per Mahshid's request) |
||
| (27 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Strongyloidiasis}} | {{Strongyloidiasis}} | ||
{{CMG}}; {{AE}} {{ADG}} | |||
==Overview== | ==Overview== | ||
If left untreated, the | If strongyloidiasis is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or who are otherwise immunocompromised), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in patients with a [[immunosuppression|suppressed immune system]]. | ||
==Natural history== | ==Natural history== | ||
If left untreated, the subclinical strongyloidiasis can disseminate and transform into | If left untreated, the subclinical [[strongyloidiasis]] can disseminate and transform into [[Hyper infection syndrome|hyperinfection syndrome]], which has a [[mortality]] rate of 90%.<ref name="pmid27213420">{{cite journal |vauthors=Beknazarova M, Whiley H, Ross K |title=Strongyloidiasis: A Disease of Socioeconomic Disadvantage |journal=Int J Environ Res Public Health |volume=13 |issue=5 |pages= |year=2016 |pmid=27213420 |pmc=4881142 |doi=10.3390/ijerph13050517 |url=}}</ref> | ||
==Complications== | ==Complications== | ||
Complications that can develop as a result of strongyloidiasis are | Complications that can develop as a result of strongyloidiasis are:<ref name="pmid16304332">{{cite journal |vauthors=Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF |title=Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis |journal=Chest |volume=128 |issue=5 |pages=3681–4 |year=2005 |pmid=16304332 |pmc=1941746 |doi=10.1378/chest.128.5.3681 |url=}}</ref><ref name="GomezMaque2013">{{cite journal|last1=Gomez|first1=Juliana B.|last2=Maque|first2=Yvan|last3=Moquillaza|first3=Manuel A.|last4=Anicama|first4=William E.|title=E. coliMeningitis Presenting in a Patient with DisseminatedStrongyloides stercoralis|journal=Case Reports in Infectious Diseases|volume=2013|year=2013|pages=1–4|issn=2090-6625|doi=10.1155/2013/424362}}</ref> | ||
* Disseminated strongyloidiasis | * [[Strongyloidiasis|Disseminated strongyloidiasis]](especially in patients with [[HIV]] and other [[immunocompromised]] conditions) | ||
* Eosinophilic pneumonia | * [[Sepsis causes|Polymicrobial sepsis]] including [[Meningitis causes|polymicrobial gram-negative meningitis]] | ||
* [[Malnutrition]] | * [[Eosinophilic pneumonia]] | ||
* [[Malnutrition]] | |||
* [[Malabsorption]] | |||
* [[Intestinal perforation]] | |||
==Prognosis== | ==Prognosis== | ||
With | *With appropriate treatment people should make a full recovery. | ||
* | *Sometimes, treatment needs to be repeated due to autoinfection. | ||
*HTLV-1 infection | *Infections that are severe or widespread often have a poor outcome, especially in patients with a [[immunosuppression|suppressed immune system]]. | ||
* | *[[Strongyloidiasis]] could be severe and life-threatening in specific groups including: | ||
*Transplant recipients. | **Those who use oral or [[intravenous]] [[steroids]], for example, in patients with [[asthma]], [[chronic obstructive pulmonary disease]] ([[COPD]]) exacerbations, [[lupus]], [[gout]], or in persons using [[steroids]] for [[immunosuppression]] or symptomatic relief | ||
**Those with [[HTLV-1]] infection | |||
**Those with [[hematologic]] [[malignancies]] such as [[leukemia]] or [[lymphoma]] | |||
**[[Transplant|Transplant recipients]] | |||
*Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%. | |||
==References== | ==References== | ||
| Line 25: | Line 34: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:52, 18 September 2017
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis natural history, complications and prognosis |
|
FDA on Strongyloidiasis natural history, complications and prognosis |
|
CDC on Strongyloidiasis natural history, complications and prognosis |
|
Strongyloidiasis natural history, complications and prognosis in the news |
|
Blogs on Strongyloidiasis natural history, complications and prognosis |
|
Risk calculators and risk factors for Strongyloidiasis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with HIV or who are otherwise immunocompromised), eosinophilic pneumonia, malnutrition, and malabsorption. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. Infections that are severe or widespread often have a poor outcome, especially in patients with a suppressed immune system.
Natural history
If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%.[1]
Complications
Complications that can develop as a result of strongyloidiasis are:[2][3]
- Disseminated strongyloidiasis(especially in patients with HIV and other immunocompromised conditions)
- Polymicrobial sepsis including polymicrobial gram-negative meningitis
- Eosinophilic pneumonia
- Malnutrition
- Malabsorption
- Intestinal perforation
Prognosis
- With appropriate treatment people should make a full recovery.
- Sometimes, treatment needs to be repeated due to autoinfection.
- Infections that are severe or widespread often have a poor outcome, especially in patients with a suppressed immune system.
- Strongyloidiasis could be severe and life-threatening in specific groups including:
- Those who use oral or intravenous steroids, for example, in patients with asthma, chronic obstructive pulmonary disease (COPD) exacerbations, lupus, gout, or in persons using steroids for immunosuppression or symptomatic relief
- Those with HTLV-1 infection
- Those with hematologic malignancies such as leukemia or lymphoma
- Transplant recipients
- Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%.
References
- ↑ Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.
- ↑ Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF (2005). "Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis". Chest. 128 (5): 3681–4. doi:10.1378/chest.128.5.3681. PMC 1941746. PMID 16304332.
- ↑ Gomez, Juliana B.; Maque, Yvan; Moquillaza, Manuel A.; Anicama, William E. (2013). "E. coliMeningitis Presenting in a Patient with DisseminatedStrongyloides stercoralis". Case Reports in Infectious Diseases. 2013: 1–4. doi:10.1155/2013/424362. ISSN 2090-6625.